general
Lilly sets up next-gen obesity battle with full phase 3 retatrutide data
Eli Lilly has shared detailed data from a p
Eli Lilly has shared detailed data from a phase 3 retatrutide trial, revealing that more than one-third of patients on the top dose of the triple-G drug candidate lost at least 25% of their body weight.
Lilly reported topline data from the trial, Tri... [2905 chars]
Read Full ArticleShare this story
Up next
Related Stories
Helicopter crashes off Catalina Island coast, rescue efforts underway
CBS News
The Cornell Rape Investigation: Five Takeaways
The New York Times
How a Cornell Student Went From Shame to Seeking Justice
The New York Times
Extended interview: Best friends navigating a cancer diagnosis
CBS News
In photos: China's Xi hardens Taiwan warning as country celebrates week-long National Day holiday
cnbc.com